ClinicalTrials.gg
CompletedNCT02542254Updated Sep 9, 2016

The Effects of RPL554 on Top of Standard COPD Reliever Medications

A Phase 2 interventional study of Salbutamol and Ipratropium in Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma plc. Completed at 1 site in United Kingdom. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-09-09.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, 1 under way, none of them phase 3. Albuterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
13th of 27
36 · median 33
Started
2015
the only one that year
Phase 2
2 of 27
none open now
Registered
19th of 27
by date

Among the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive, this one is the 13th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 2, and was the 19th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

This study evaluates the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disorder (COPD). All patients will receive the same six treatments in a randomised sequence:

  1. salbutamol,
  2. ipratropium,
  3. salbutamol + RPL554,
  4. ipratropium + RPL554,
  5. RPL554
  6. Placebo
Read the detailed description

The purpose of this study is to investigate if RPL554 has an additive bronchodilator effect when administered in combination with standard of care bronchodilators in patients with COPD.This study investigates the pharmacodynamic effect of RPL554 using spirometry and whole body plethysmography compared to placebo, when administered in addition to a beta2 agonist (salbutamol), a muscarinic antagonist (ipratropium) or placebo.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide
  • Males not donating sperm and using adequate or females who are surgically sterile or
  • 12-lead showing:Heart rate 45 to 90 bpm, ≤450 msec, QRS ≤120 msec, PR interval ≤220 msec, no abnormality
  • Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.
  • 18 to 33 kg/m2 with a minimum weight of 45 kg.
  • diagnosis for at least 1 year and clinically stable COPD in previous 4 weeks
  • Demonstrates reversibility to bronchodilator (two puffs of salbutamol followed by two puffs of ipratropium) via spirometry:

    • Post-bronchodilator /forced vital capacity (FVC) ratio of ≤0.70
    • Post-bronchodilator FEV1 ≥40 % and ≤80% of predicted normal
    • ≥150 mL increase from pre-bronchodilator FEV1
  • Chest X-ray showing no abnormalities
  • Meet the concomitant medication restrictions and be expected to do so for the rest of the study.
  • Smoking history of ≥10 pack years.
  • Capable of withdrawing from long acting bronchodilators throughout the study and short acting bronchodilators for 8 hours prior to study treatment.

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening including Intensive Care Unit admission and/or requiring intubation.
  • COPD exacerbation requiring oral in the previous 3 months
  • History of one or more hospitalisations for COPD in the previous 12 months
  • Respiratory tract infection (both upper and lower) treated with antibiotics in previous 12 weeks
  • Evidence of cor pulmonale or pulmonary hypertension.
  • Other respiratory disorders
  • Previous lung resection or lung reduction surgery.
  • Oral therapies for COPD in the previous 3 months and throughout the study.
  • Drug or alcohol abuse in the past 3 years
  • Received an experimental drug within 3 months or five half lives, whichever is longer.
  • Prior exposure to RPL554
  • Patients with a history of chronic uncontrolled disease that the Investigator believes are clinically significant.
  • Documented cardiovascular disease in last 3 months
  • Major surgery, (requiring general anaesthesia) in the previous 6 weeks, or will not have fully recovered from surgery, or planned surgery through the end of the study.
  • History of of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell)
  • Clinically significant abnormal values for safety laboratory tests
  • A disclosed history, or one known to the Investigator, of significant non compliance in previous studies or with prescribed medications.
  • Requires oxygen therapy, even on an occasional basis.
  • Inability to adequately perform whole body plethysmography.
  • Any other reason that the Investigator considers makes the subject unsuitable to participate.
  • Patients with known to atropine or its derivatives, or to ipratropium bromide, salbutamol or RPL554 or their /components.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Salbutamol alone

    200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo

    Drug: Salbutamol · Drug: Ipratropium matched placebo · Drug: RPL554 matched placebo

  • Experimental
    Salbutamol and RPL554

    200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554

    Drug: Salbutamol · Drug: RPL554 · Drug: Ipratropium matched placebo

  • Active comparator
    Ipratropium

    Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo

    Drug: Ipratropium · Drug: Salbutamol matched placebo · Drug: RPL554 matched placebo

  • Experimental
    Ipratropium and RPL554

    Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554

    Drug: Ipratropium · Drug: RPL554 · Drug: Salbutamol matched placebo

  • Experimental
    RPL554

    Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554

    Drug: RPL554 · Drug: Salbutamol matched placebo · Drug: Ipratropium matched placebo

  • Placebo comparator
    Placebo

    Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo

    Drug: Salbutamol matched placebo · Drug: Ipratropium matched placebo · Drug: RPL554 matched placebo

Interventions

  • 200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)

  • 40 micrograms ipratropium administered using a pMDI

  • DrugRPL554

    6 mg RPL554 administered using a nebuliser

  • DrugSalbutamol matched placebo

    Placebo pMDI

  • DrugIpratropium matched placebo

    Placebo pMDI

  • DrugRPL554 matched placebo

    Nebulised placebo

06

What researchers measure

Primary outcomes

  1. 8 hour spirometry

    Forced expired volume in one second (FEV1) over 8 hours post-dose

    Time frame: 8 hours

Secondary outcomes

  1. 12 hour spirometry

    FEV1 over 4, 6 and 12 hours post-dose

    Time frame: 12 hours

  2. Whole body plethysmography

    Functional residual capacity, residual volume, total lung capacity, specific airway conductance, specific airway resistance at 1 and 4 hours post-dose

    Time frame: 4 hours

  3. Area under the curve (AUC)

    AUC for RPL554 plasma concentration

    Time frame: 12 hours

  4. Maximum plasma concentration (Cmax)

    Cmax for RPL554 plasma concentration

    Time frame: 12 hours

  5. Time to maximum plasma concentration (Tmax)

    Tmax for RPL554 plasma concentration

    Time frame: 12 hours

  6. Adverse events

    Continuous measurement of adverse events throughout the study

    Time frame: Up to 94 days

  7. Safety laboratory tests

    Laboratory safety tests at screening, before each treatment and end of study

    Time frame: Up to 94 days

  8. ECG

    12 lead ECG at screening, before and up to 12 hours after each treatment and end of study

    Time frame: Up to 94 days

  9. Vital signs

    Blood pressure and pulse rate at screening, before and up to 12 hours after each treatment and end of study

    Time frame: Up to 94 days

07

Study locations

1 site
  • Medicines Evaluation Unit
    Manchester, United Kingdom
08

References and documents

Publications

  • Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018 Nov 1;52(5):1801074. doi: 10.1183/13993003.01074-2018. Print 2018 Nov. PubMed 30166326 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2015
First posted
Sep 4, 2015
Start
Oct 2015
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Last update
Sep 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02542254
Lead sponsor
Verona Pharma plc
Responsible party
Sponsor
First posted
Sep 4, 2015
Start date
Oct 2015
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Sep 9, 2016

Study contacts

Dave Singh
principal investigator · Medicines Evaluation Unit

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albuterol · Ipratropium · Ensifentrine

Start the discussion